# HealthLynked Corp: overview HLYK · OTC · CIK 1680139 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/hlyk.md) · [Financials](/companies/hlyk/financials.md) · [Filings](/companies/hlyk/filings.md) · [Insiders](/companies/hlyk/insiders.md) Latest reported revenue: [$249.8k](/filings/0001213900-26-090221.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 14, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax, accession 0001213900-26-090221). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [590](/filings/0001213900-24-098383.md) | [619 d](/filings/0001213900-25-026262.md) | [774](/filings/0001213900-26-057581.md) | [592](/filings/0001213900-26-090221.md) | [389](/filings/0001213900-25-112578.md) | [310 d](/filings/0001213900-26-037499.md) | [423](/filings/0001213900-26-057581.md) | [250](/filings/0001213900-26-090221.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(283.2%)](/filings/0001213900-25-112578.md) | [(121.0%) d](/filings/0001213900-26-037499.md) | [(79.7%)](/filings/0001213900-26-057581.md) | [(73.5%)](/filings/0001213900-26-090221.md) | [(136.3%)](/filings/0001213900-25-112578.md) | [(171.2%) d](/filings/0001213900-26-037499.md) | [(165.5%)](/filings/0001213900-26-057581.md) | [(215.7%)](/filings/0001213900-26-090221.md) | | Net margin | % | [(334.4%)](/filings/0001213900-25-112578.md) | [(198.8%) d](/filings/0001213900-26-037499.md) | [(135.7%)](/filings/0001213900-26-090221.md) | [(118.3%)](/filings/0001213900-26-090221.md) | [(219.2%)](/filings/0001213900-25-112578.md) | [(218.1%) d](/filings/0001213900-26-037499.md) | [(382.9%)](/filings/0001213900-26-090221.md) | [(328.1%)](/filings/0001213900-26-090221.md) | | Diluted EPS | $ per share | [(0.70)](/filings/0001213900-25-112578.md) | not reported | [(0.37)](/filings/0001213900-26-057581.md) | [(0.25)](/filings/0001213900-26-090221.md) | [(0.30)](/filings/0001213900-25-112578.md) | not reported | [(0.56)](/filings/0001213900-26-057581.md) | [(0.28)](/filings/0001213900-26-090221.md) | | Free cash flow | $k | [(1,037) d](/filings/0001213900-25-112578.md) | [(744) d](/filings/0001213900-26-037499.md) | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [6,497](/filings/0001213900-23-025432.md) | [5,858](/filings/0001213900-24-028696.md) | [5,722](/filings/0001213900-25-026262.md) | [3,008](/filings/0001213900-25-026262.md) | [2,065](/filings/0001213900-26-037499.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(82.1%)](/filings/0001213900-23-025432.md) | [(147.8%)](/filings/0001213900-24-028696.md) | [(72.6%)](/filings/0001213900-25-026262.md) | [(155.5%)](/filings/0001213900-26-037499.md) | [(102.3%)](/filings/0001213900-26-037499.md) | | Net margin | % | [(160.3%)](/filings/0001213900-23-025432.md) | [(150.5%)](/filings/0001213900-24-028696.md) | [(17.7%)](/filings/0001213900-25-026262.md) | [(203.8%)](/filings/0001213900-26-037499.md) | [(158.8%)](/filings/0001213900-26-037499.md) | | Diluted EPS | $ per share | [(0.05)](/filings/0001213900-23-025432.md) | [(0.04)](/filings/0001213900-24-028696.md) | [0.00](/filings/0001213900-25-026262.md) | [(2.18)](/filings/0001213900-26-037499.md) | [(1.16)](/filings/0001213900-26-037499.md) | | Free cash flow | $k | [(3,789)](/filings/0001213900-23-025432.md) | [(4,387)](/filings/0001213900-24-028696.md) | [(4,146)](/filings/0001213900-25-026262.md) | [(3,497)](/filings/0001213900-26-037499.md) | not reported | - Revenue. XBRL Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/hlyk/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Ancora Advisors LLC](/funds/1446114.md) | 2026-06-30 | $222 | 74 | | Unchanged | ## Recent filings [All 224 filings](/companies/hlyk/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-14 | 16:57 ET | [10-Q](/filings/0001213900-26-090221.md) | Quarterly report, period 2026-06-30 | 0001213900-26-090221 | | 2026-07-16 | 16:02 ET | [8-K](/filings/0001213900-26-078695.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001213900-26-078695 | | 2026-05-29 | 16:39 ET | [S-1/A](/filings/0001213900-26-062879.md) | Registration statement, amended | 0001213900-26-062879 | | 2026-05-15 | 15:00 ET | [10-Q](/filings/0001213900-26-057581.md) | Quarterly report, period 2026-03-31 | 0001213900-26-057581 | | 2026-04-30 | 16:33 ET | [S-1/A](/filings/0001213900-26-050297.md) | Registration statement, amended | 0001213900-26-050297 | | 2026-03-31 | 16:30 ET | [10-K](/filings/0001213900-26-037499.md) | Annual report, period 2025-12-31 | 0001213900-26-037499 | | 2026-02-10 | 19:29 ET | [S-1](/filings/0001213900-26-013824.md) | Registration statement | 0001213900-26-013824 | | 2026-02-06 | 16:00 ET | [8-K](/filings/0001213900-26-013261.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001213900-26-013261 | | 2025-12-12 | 16:00 ET | [8-K](/filings/0001213900-25-121170.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001213900-25-121170 | | 2025-11-19 | 15:29 ET | [10-Q](/filings/0001213900-25-112578.md) | Quarterly report, period 2025-09-30 | 0001213900-25-112578 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001213900-26-037499.md), filed Mar 31, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/51117dbb-64af-4cb5-ae67-eadb40b3f21a) ## About the filer - CIK: 1680139 - Tickers: HLYK - Exchange: OTC - SIC code: 8011 Services-Offices & Clinics of Doctors of Medicine - State of incorporation: NV - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.